Accéder au contenu
Merck
Toutes les photos(2)

Key Documents

14701C

SAFC

EX-CELL® Glycosylation Adjust (Gal +)

protein quality supplement

Synonyme(s) :

N-linked glycosylation reagent

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Code UNSPSC :
12352207
Nomenclature NACRES :
NA.75

Forme

liquid

Qualité

GMP
chemically defined

Technique(s)

cell culture | mammalian: suitable

Impuretés

Sterility Tested, pH, Endotoxin, and Appearance

Adéquation

suitable for manufacturing use

Température de stockage

2-8°C

Description générale

A protein quality supplement that targets glycosylation attributes, EX-CELL® Glycosylation Adjust (Gal+) allows users to easily and quickly achieve desired N-linked glycosylation by increasing the galactose site occupancy on the oligosaccharide to a higher level. Supplementation demonstrates 2- to 4-fold increases in G1F and G2F distributions when compared to processes without addition of the product. The product can be used with a broad range of cell lines, is scalable, and is regulatory friendly.
GMP concentrated solution. Intended as a cell culture supplement. Recommended titration starting point, % volume/volume.

Conditionnement

14701C-100ML
14701C-1000ML

Liaison

Submit the EX-CELL Glycosylation Adjust (Gal +) request form to get in touch with a SAFC representative.

Informations légales

EX-CELL is a registered trademark of Merck KGaA, Darmstadt, Germany

Code de la classe de stockage

10 - Combustible liquids

Classe de danger pour l'eau (WGK)

WGK 3


Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Articles

Our protein quality supplement, EX-CELL® Glycosylation Adjust (Gal+), provides customers with a novel chemically defined product which targets glycosylation attributes.

The biosimilar market is expected to grow rapidly in the coming years, as many blockbuster monoclonal antibodies lose patent protection by 2020.

The biosimilar market is expected to grow rapidly in the coming years, as many blockbuster monoclonal antibodies lose patent protection by 2020.

The biosimilar market is expected to grow rapidly in the coming years, as many blockbuster monoclonal antibodies lose patent protection by 2020.

Afficher tout

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique